Member Info for B_Positive

Yes NAV around 3-4p and rising as IR gets close to listing.

Remember the CEO is eyeing a valuation of $1tril for it.

If it gets to even a $100bil the MFAI NAV would be around 30p.

I'm sure many here would be happy with 30bags or 3,000%.

Very doable.

IR aka Napster would not have received $3bil in funding from investors if it didn't intend to go through with its plans..

Once the updates is in it's going to demonstrate how big MFAI is and undervalued just for Napster alone.

Update next week would be fab.

You forget the monster Infinite Reality

Thus I hold for the pennies which will come very quickly.

Next week am feeling great things here

I fancy a stonking RNS wave here

Didn't sell as I'd much rather be in than out from here.

Aerospace vendor loves the tech and others will too

Placing and traders gone so I fancy a glide above 2.00p by close today and 3.00p next week even without news.

But as FDA, partners and global expansion news is close if an RNS drops next week then 5.00p quickly and a steady climb from here.

This test is absolutely excellent and with one big pharma deal it wont be at 2p, or 10p, but shares will be trading well over 20p easily.

Remember its not just stroke but also now cardovasculiar.

NHS national rollout underway and global expansion news next.

Ridiculous when its trading over 20p from just one big pharma deal

Sub 10p buys will look absolutely

Very soon sub 10p shares will be have been viewed as an absolute GIFT.

Entire NHS supply chain buying these tests.

Look at the endorsement

This chap who's the clinical lead for the Stroke Service at North West Anglia NHS Trust likes Genedrives linkedin post on the announcement today

Here's his profile

https://www.linkedin.com/in/radim-licenik-a2977527?utm_source=share&utm_campaign=share_via&utm_content=profile&utm_medium=android_app

And here's gdr's post

https://www.linkedin.com/posts/genedrive-plc_gdr-poct-pharmacogenomics-activity-7334159231895457792-mR8B?utm_source=share&utm_medium=member_android&rcm=ACoAAEG4l0gBO7-otCES7DDpar2cXo5aD5L2eLY

Also this international product manager at Roche likes the GDR CEO post today

Here's her profile

https://www.linkedin.com/in/debs-hepburn-4a088536?utm_source=share&utm_campaign=share_via&utm_content=profile&utm_medium=android_app

And here's Gino's post from today

https://www.linkedin.com/posts/ginomiele_gdr-poct-pharmacogenomics-activity-7334166692777877504-9qhd?utm_source=share&utm_medium=member_android&rcm=ACoAAEG4l0gBO7-otCES7DDpar2cXo5aD5L2eLY

And now this chap a Director of Regulatory Affairs FDA & EU from Edward Lifesciences Georgia USA reacting to Gino's post today get that??

Here's his profile and look at his previous experience

https://www.linkedin.com/in/roberto-f-refeca-b69063288?utm_source=share&utm_campaign=share_via&utm_content=profile&utm_medium=android_app

Newsflash the majority of AIM stocks get by from raising equity, but that doesn't stop them rising considerably.

Some rise 1000-2000% before they raise and ENET from here is one of those candidated from a £1m cap and with revenues and more contracts to come.

Resolving Ethernity's status as a company that operates under a creditor settlement arrangement is a critical step towards strengthening the Company's financial position, restoring supplier and partner confidence, and improving overall operational flexibility.

Clearing this issue will not only enhance the Company's credibility in the market but also position it more favorably for strategic growth initiatives, including the ASIC development and long-term partnerships as detailed in the 2024 Trading Update.

Additionally, the ASIC plan - now expanded to include support for Passive Optical Network ("PON") functionality - will further strengthen the Company's ability to re-engage with OEMs that previously evaluated our FPGA-based UEP solutions. With the availability of the ASIC, these OEMs would be able to access groundbreaking, high-performance appliances, significantly enhancing their own market offerings.

Dr Dan Gooding, Executive Director: Achieved licensing deal with Johnson & Johnson and AstraZeneca

Dan supported Qureight Ltd develops AI-based image processing methods in measuring disease progression for patients with fibrotic lung diseases incl IPF

Orphan Drug Designation should significantly support our goal of progressing NXP002 through partnering and further development activities and, ultimately bringing solutions for fibrotic ILD indications to patients. We're thrilled that like us, the EMA has recognised the promise of this potential breakthrough medicine. We will now submit an application for US FDA orphan drug designation and continue discussions with potential future licensing partners and will provide further updates in due course as appropriate."

Genedrivegenedrive

4,707 followers4,707 followers

4d • 4 days ago • Visible to anyone on or off LinkedIn

We are delighted that both of our pharmacogenetic tests are now available for order via the NHS supply chain!

Contact enquiries@genedrive.com for more information

hashtag#GDR hashtag#pharmacogenomics hashtag#pharmacogenetics hashtag#diagnostics hashtag#POCT hashtag#genetics hashtag#pointofcare hashtag#NHS

This is AIM, if you want profitable companies then you don't invest in AIM LOL

Many AIM companies with no revenue and many debts valued at £10-£100MIL

Therefore this with 0 debt and with revenues at a £1m mcap is a great opportunity for myself

Next RNS feels very close and could be the ASIC whopper for $16mil contract

Update will see this on the trajectory to at least 0.20p.

Of course a big contract and it goes to 0.50p with ease.

Resolving Ethernity's status as a company that operates under a creditor settlement arrangement is a critical step towards strengthening the Company's financial position, restoring supplier and partner confidence, and improving overall operational flexibility.

Clearing this issue will not only enhance the Company's credibility in the market but also position it more favorably for strategic growth initiatives, including the ASIC development and long-term partnerships as detailed in the 2024 Trading Update.

Additionally, the ASIC plan - now expanded to include support for Passive Optical Network ("PON") functionality - will further strengthen the Company's ability to re-engage with OEMs that previously evaluated our FPGA-based UEP solutions. With the availability of the ASIC, these OEMs would be able to access groundbreaking, high-performance appliances, significantly enhancing their own market offerings.

Share price a gross undervaluation and can 10x from here and still be cheap.

Gold project targeting has proven over 90% recovery rates and is targeting millions of ounces.

Even 100,000oz of gold x $3,300 gold price = $330,000,000 MILLION.

Massive massive undervaluation of ORCP considering the stable.

Even just achieve 1/20th of the MINIMUM exploration target of 2.5mil oz, which is 125koz we are looking at an in ground value of:

US$412.5 MILLION

At a gold price of $3300.

Meanwhile many predict a $4000+ gold price this year.

The results from this phase confirmed an exploration target of 200-250 million tonnes at a grade of 0.4-0.6 grams per tonne (g/t) gold, translating to an estimated 2.5 to 4.8 million ounces of gold. Subsequent metallurgical testing indicated promising gold recovery rates, with up to 90.4% recovery over 72 hours

Then do the math on if they get over 1,000,000oz....

Rereate